Core Clinical Molecular Diagnostics Market By Product type (Instruments, Reagents, Software and Services), By Technique (PCR, Nucleic Acid Sequencing, Fluorescence In Situ Hybridization (FISH), Others), By Application (Infectious Disease, Genetic disorder, Cancer Screening, Others): Global Opportunity Analysis and Industry Forecast, 2022 - 2032
The core clinical molecular diagnostics market was valued at $4.8 billion in 2022 and is estimated to reach $11.9 billion by 2032, exhibiting a CAGR of 9.50% from 2023 to 2032. Core clinical molecular diagnostics refer to essential techniques and procedures conducted in medical laboratories. They focus on analyzing genetic material (DNA, RNA) and proteins at the molecular level to diagnose diseases and guide treatment decisions. These diagnostics encompass various methodologies such as Polymerase Chain Reaction (PCR), DNA sequencing, Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), and immunohistochemistry (IHC). Core clinical molecular diagnostics play a crucial role in personalized medicine by identifying genetic variations, infectious agents, and biomarkers associated with diseases, enabling tailored patient care and improving clinical outcomes.
The increasing prevalence of diseases and the aging population are major driving forces behind the growing demand for core clinical molecular diagnostics. As populations age, the incidence of chronic and age-related diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders rises significantly. Additionally, the aging demographic is more susceptible to infectious diseases due to weakened immune systems. According to data obtained from the U.S. Census Bureau, in 2021, elderly population in the U.S. accounted for 16.5% of the total population, which is 54 million. Moreover, this number is anticipated to increase to 85.7 million by 2050. In addition, according to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer.
Thus, clinical molecular diagnostics play a critical role in accurately diagnosing these conditions by identifying genetic variations, infectious agents, and biomarkers associated with specific diseases. Their ability to provide precise and timely diagnostic information enables healthcare providers to implement personalized treatment strategies, improving patient outcomes and contributing to more effective disease management in an aging population. As such, the demand for core clinical molecular diagnostics is expected to continue increasing to meet the healthcare needs of aging populations worldwide.
In addition, the rising expenditure in healthcare is indeed a significant driver propelling the growth of the core clinical molecular diagnostics market. As healthcare spending increases globally, there's a greater emphasis on improving diagnostic capabilities to enhance patient care and outcomes. The ability of clinical core molecular diagnostics offers precise and personalized diagnostic information, which aligns well with the growing trend towards precision medicine. With more resources being allocated to healthcare, there's an increased ability and willingness to invest in advanced diagnostic technologies such as PCR, DNA sequencing, and NGS, driving market growth. Additionally, as healthcare systems strive to optimize resource utilization and improve cost-effectiveness, the efficiency and accuracy offered by core clinical molecular diagnostics become increasingly attractive, further fueling market expansion.
The core clinical molecular diagnostics market is segmented on the basis of product type, technique, application, and region. On the basis of product type, the market is segmented into Instruments, reagents and software & services. On the basis of technique, the market is segmented into PCR, nucleic acid sequencing, fluorescence in situ hybridization (FISH), and others. On the basis of application, the market is segmented into infectious diseases, genetic disorders, cancer screening, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).
The major key players that operate in the core clinical molecular diagnostics market are F. Hoffmann-La Roche Ltd., Novartis, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, Agilent Technologies, Hologic, Inc. Bio-Rad Laboratories, Inc., Qiagen and bioM?rieux. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.
Key Benefits for Stakeholders
The increasing prevalence of diseases and the aging population are major driving forces behind the growing demand for core clinical molecular diagnostics. As populations age, the incidence of chronic and age-related diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders rises significantly. Additionally, the aging demographic is more susceptible to infectious diseases due to weakened immune systems. According to data obtained from the U.S. Census Bureau, in 2021, elderly population in the U.S. accounted for 16.5% of the total population, which is 54 million. Moreover, this number is anticipated to increase to 85.7 million by 2050. In addition, according to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer.
Thus, clinical molecular diagnostics play a critical role in accurately diagnosing these conditions by identifying genetic variations, infectious agents, and biomarkers associated with specific diseases. Their ability to provide precise and timely diagnostic information enables healthcare providers to implement personalized treatment strategies, improving patient outcomes and contributing to more effective disease management in an aging population. As such, the demand for core clinical molecular diagnostics is expected to continue increasing to meet the healthcare needs of aging populations worldwide.
In addition, the rising expenditure in healthcare is indeed a significant driver propelling the growth of the core clinical molecular diagnostics market. As healthcare spending increases globally, there's a greater emphasis on improving diagnostic capabilities to enhance patient care and outcomes. The ability of clinical core molecular diagnostics offers precise and personalized diagnostic information, which aligns well with the growing trend towards precision medicine. With more resources being allocated to healthcare, there's an increased ability and willingness to invest in advanced diagnostic technologies such as PCR, DNA sequencing, and NGS, driving market growth. Additionally, as healthcare systems strive to optimize resource utilization and improve cost-effectiveness, the efficiency and accuracy offered by core clinical molecular diagnostics become increasingly attractive, further fueling market expansion.
The core clinical molecular diagnostics market is segmented on the basis of product type, technique, application, and region. On the basis of product type, the market is segmented into Instruments, reagents and software & services. On the basis of technique, the market is segmented into PCR, nucleic acid sequencing, fluorescence in situ hybridization (FISH), and others. On the basis of application, the market is segmented into infectious diseases, genetic disorders, cancer screening, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).
The major key players that operate in the core clinical molecular diagnostics market are F. Hoffmann-La Roche Ltd., Novartis, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, Agilent Technologies, Hologic, Inc. Bio-Rad Laboratories, Inc., Qiagen and bioM?rieux. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the core clinical molecular diagnostics market analysis from 2022 to 2032 to identify the prevailing core clinical molecular diagnostics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the core clinical molecular diagnostics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global core clinical molecular diagnostics market trends, key players, market segments, application areas, and market growth strategies.
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
- Reagents
- Software and Services
- Nucleic Acid Sequencing
- Fluorescence In Situ Hybridization (FISH)
- Others
- Genetic disorder
- Cancer Screening
- Others
- North America U.S.
- Canada
- Mexico
- Europe Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America Brazil
- Colombia
- Argentina
- Rest Of La
- Middle East and Africa Gcc
- South Africa
- North Africa
- Rest Of Mea
- F. Hoffmann La Roche
- Novartis AG
- Abbott Laboratories
- Becton Dickinson & Company
- Siemens Healthineers AG
- Agilent Technologies, Inc.
- Hologic, Inc.
- BioMerieux SA
- Qiagen NV.
- cepheid ab
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing adoption of advanced molecular technologies such as PCR, NGS, FISH, and automated platforms
3.4.1.2. Rising prevalence of infectious diseases, cancer, and genetic disorders globally
3.4.1.3. Growing demand for personalized medicine, early disease detection, and precision diagnostics
3.4.2. Restraints
3.4.2.1. Limited reimbursement policies and regulatory complexities in some regions
3.4.3. Opportunities
3.4.3.1. Growth Opportunities in Emerging Markets
CHAPTER 4: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Reagents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Software and Services
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
5.1. Overview
5.1.1. Market size and forecast
5.2. PCR
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Nucleic Acid Sequencing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Fluorescence In Situ Hybridization (FISH)
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Infectious Disease
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Genetic disorder
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Cancer Screening
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Product type
7.2.3. Market size and forecast, by Technique
7.2.4. Market size and forecast, by Application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Product type
7.2.5.1.2. Market size and forecast, by Technique
7.2.5.1.3. Market size and forecast, by Application
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Product type
7.2.5.2.2. Market size and forecast, by Technique
7.2.5.2.3. Market size and forecast, by Application
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Product type
7.2.5.3.2. Market size and forecast, by Technique
7.2.5.3.3. Market size and forecast, by Application
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Product type
7.3.3. Market size and forecast, by Technique
7.3.4. Market size and forecast, by Application
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Product type
7.3.5.1.2. Market size and forecast, by Technique
7.3.5.1.3. Market size and forecast, by Application
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Product type
7.3.5.2.2. Market size and forecast, by Technique
7.3.5.2.3. Market size and forecast, by Application
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Product type
7.3.5.3.2. Market size and forecast, by Technique
7.3.5.3.3. Market size and forecast, by Application
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Product type
7.3.5.4.2. Market size and forecast, by Technique
7.3.5.4.3. Market size and forecast, by Application
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Product type
7.3.5.5.2. Market size and forecast, by Technique
7.3.5.5.3. Market size and forecast, by Application
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Product type
7.3.5.6.2. Market size and forecast, by Technique
7.3.5.6.3. Market size and forecast, by Application
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Product type
7.4.3. Market size and forecast, by Technique
7.4.4. Market size and forecast, by Application
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Product type
7.4.5.1.2. Market size and forecast, by Technique
7.4.5.1.3. Market size and forecast, by Application
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Product type
7.4.5.2.2. Market size and forecast, by Technique
7.4.5.2.3. Market size and forecast, by Application
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Product type
7.4.5.3.2. Market size and forecast, by Technique
7.4.5.3.3. Market size and forecast, by Application
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Product type
7.4.5.4.2. Market size and forecast, by Technique
7.4.5.4.3. Market size and forecast, by Application
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Product type
7.4.5.5.2. Market size and forecast, by Technique
7.4.5.5.3. Market size and forecast, by Application
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Product type
7.4.5.6.2. Market size and forecast, by Technique
7.4.5.6.3. Market size and forecast, by Application
7.5. Latin America
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Product type
7.5.3. Market size and forecast, by Technique
7.5.4. Market size and forecast, by Application
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Product type
7.5.5.1.2. Market size and forecast, by Technique
7.5.5.1.3. Market size and forecast, by Application
7.5.5.2. Colombia
7.5.5.2.1. Market size and forecast, by Product type
7.5.5.2.2. Market size and forecast, by Technique
7.5.5.2.3. Market size and forecast, by Application
7.5.5.3. Argentina
7.5.5.3.1. Market size and forecast, by Product type
7.5.5.3.2. Market size and forecast, by Technique
7.5.5.3.3. Market size and forecast, by Application
7.5.5.4. Rest Of La
7.5.5.4.1. Market size and forecast, by Product type
7.5.5.4.2. Market size and forecast, by Technique
7.5.5.4.3. Market size and forecast, by Application
7.6. Middle East and Africa
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by Product type
7.6.3. Market size and forecast, by Technique
7.6.4. Market size and forecast, by Application
7.6.5. Market size and forecast, by country
7.6.5.1. Gcc
7.6.5.1.1. Market size and forecast, by Product type
7.6.5.1.2. Market size and forecast, by Technique
7.6.5.1.3. Market size and forecast, by Application
7.6.5.2. South Africa
7.6.5.2.1. Market size and forecast, by Product type
7.6.5.2.2. Market size and forecast, by Technique
7.6.5.2.3. Market size and forecast, by Application
7.6.5.3. North Africa
7.6.5.3.1. Market size and forecast, by Product type
7.6.5.3.2. Market size and forecast, by Technique
7.6.5.3.3. Market size and forecast, by Application
7.6.5.4. Rest Of Mea
7.6.5.4.1. Market size and forecast, by Product type
7.6.5.4.2. Market size and forecast, by Technique
7.6.5.4.3. Market size and forecast, by Application
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Becton Dickinson & Company
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Siemens Healthineers AG
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Agilent Technologies, Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Hologic, Inc.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. BioMerieux SA
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Qiagen NV.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. F. Hoffmann-La Roche Ltd.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Danaher Corporation
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Thermo Fisher Scientific Inc.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing adoption of advanced molecular technologies such as PCR, NGS, FISH, and automated platforms
3.4.1.2. Rising prevalence of infectious diseases, cancer, and genetic disorders globally
3.4.1.3. Growing demand for personalized medicine, early disease detection, and precision diagnostics
3.4.2. Restraints
3.4.2.1. Limited reimbursement policies and regulatory complexities in some regions
3.4.3. Opportunities
3.4.3.1. Growth Opportunities in Emerging Markets
CHAPTER 4: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Reagents
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Software and Services
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE
5.1. Overview
5.1.1. Market size and forecast
5.2. PCR
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Nucleic Acid Sequencing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Fluorescence In Situ Hybridization (FISH)
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Infectious Disease
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Genetic disorder
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Cancer Screening
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Others
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
CHAPTER 7: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Product type
7.2.3. Market size and forecast, by Technique
7.2.4. Market size and forecast, by Application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Product type
7.2.5.1.2. Market size and forecast, by Technique
7.2.5.1.3. Market size and forecast, by Application
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Product type
7.2.5.2.2. Market size and forecast, by Technique
7.2.5.2.3. Market size and forecast, by Application
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Product type
7.2.5.3.2. Market size and forecast, by Technique
7.2.5.3.3. Market size and forecast, by Application
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Product type
7.3.3. Market size and forecast, by Technique
7.3.4. Market size and forecast, by Application
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Product type
7.3.5.1.2. Market size and forecast, by Technique
7.3.5.1.3. Market size and forecast, by Application
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Product type
7.3.5.2.2. Market size and forecast, by Technique
7.3.5.2.3. Market size and forecast, by Application
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Product type
7.3.5.3.2. Market size and forecast, by Technique
7.3.5.3.3. Market size and forecast, by Application
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Product type
7.3.5.4.2. Market size and forecast, by Technique
7.3.5.4.3. Market size and forecast, by Application
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Product type
7.3.5.5.2. Market size and forecast, by Technique
7.3.5.5.3. Market size and forecast, by Application
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Product type
7.3.5.6.2. Market size and forecast, by Technique
7.3.5.6.3. Market size and forecast, by Application
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Product type
7.4.3. Market size and forecast, by Technique
7.4.4. Market size and forecast, by Application
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Product type
7.4.5.1.2. Market size and forecast, by Technique
7.4.5.1.3. Market size and forecast, by Application
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Product type
7.4.5.2.2. Market size and forecast, by Technique
7.4.5.2.3. Market size and forecast, by Application
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Product type
7.4.5.3.2. Market size and forecast, by Technique
7.4.5.3.3. Market size and forecast, by Application
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Product type
7.4.5.4.2. Market size and forecast, by Technique
7.4.5.4.3. Market size and forecast, by Application
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Product type
7.4.5.5.2. Market size and forecast, by Technique
7.4.5.5.3. Market size and forecast, by Application
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Product type
7.4.5.6.2. Market size and forecast, by Technique
7.4.5.6.3. Market size and forecast, by Application
7.5. Latin America
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Product type
7.5.3. Market size and forecast, by Technique
7.5.4. Market size and forecast, by Application
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Product type
7.5.5.1.2. Market size and forecast, by Technique
7.5.5.1.3. Market size and forecast, by Application
7.5.5.2. Colombia
7.5.5.2.1. Market size and forecast, by Product type
7.5.5.2.2. Market size and forecast, by Technique
7.5.5.2.3. Market size and forecast, by Application
7.5.5.3. Argentina
7.5.5.3.1. Market size and forecast, by Product type
7.5.5.3.2. Market size and forecast, by Technique
7.5.5.3.3. Market size and forecast, by Application
7.5.5.4. Rest Of La
7.5.5.4.1. Market size and forecast, by Product type
7.5.5.4.2. Market size and forecast, by Technique
7.5.5.4.3. Market size and forecast, by Application
7.6. Middle East and Africa
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by Product type
7.6.3. Market size and forecast, by Technique
7.6.4. Market size and forecast, by Application
7.6.5. Market size and forecast, by country
7.6.5.1. Gcc
7.6.5.1.1. Market size and forecast, by Product type
7.6.5.1.2. Market size and forecast, by Technique
7.6.5.1.3. Market size and forecast, by Application
7.6.5.2. South Africa
7.6.5.2.1. Market size and forecast, by Product type
7.6.5.2.2. Market size and forecast, by Technique
7.6.5.2.3. Market size and forecast, by Application
7.6.5.3. North Africa
7.6.5.3.1. Market size and forecast, by Product type
7.6.5.3.2. Market size and forecast, by Technique
7.6.5.3.3. Market size and forecast, by Application
7.6.5.4. Rest Of Mea
7.6.5.4.1. Market size and forecast, by Product type
7.6.5.4.2. Market size and forecast, by Technique
7.6.5.4.3. Market size and forecast, by Application
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Abbott Laboratories
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Becton Dickinson & Company
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Siemens Healthineers AG
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Agilent Technologies, Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Hologic, Inc.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. BioMerieux SA
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Qiagen NV.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. F. Hoffmann-La Roche Ltd.
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Danaher Corporation
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Thermo Fisher Scientific Inc.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 06. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
TABLE 07. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR NUCLEIC ACID SEQUENCING, BY REGION, 2022-2032 ($MILLION)
TABLE 08. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2022-2032 ($MILLION)
TABLE 09. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 11. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 12. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC DISORDER, BY REGION, 2022-2032 ($MILLION)
TABLE 13. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR CANCER SCREENING, BY REGION, 2022-2032 ($MILLION)
TABLE 14. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 22. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 25. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 28. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 31. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 32. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 35. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 38. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 41. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 44. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 47. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 57. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 60. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 63. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 74. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 75. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 79. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 81. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 82. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 83. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 84. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 85. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 86. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 88. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 90. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 91. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 93. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 94. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 95. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 97. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 98. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 99. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 100. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 101. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 102. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 103. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 104. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 106. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 107. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 108. ABBOTT LABORATORIES: SERVICE SEGMENTS
TABLE 109. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 110. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 111. BECTON DICKINSON & COMPANY: KEY EXECUTIVES
TABLE 112. BECTON DICKINSON & COMPANY: COMPANY SNAPSHOT
TABLE 113. BECTON DICKINSON & COMPANY: PRODUCT SEGMENTS
TABLE 114. BECTON DICKINSON & COMPANY: SERVICE SEGMENTS
TABLE 115. BECTON DICKINSON & COMPANY: PRODUCT PORTFOLIO
TABLE 116. BECTON DICKINSON & COMPANY: KEY STRATERGIES
TABLE 117. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
TABLE 118. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 119. SIEMENS HEALTHINEERS AG: PRODUCT SEGMENTS
TABLE 120. SIEMENS HEALTHINEERS AG: SERVICE SEGMENTS
TABLE 121. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 122. SIEMENS HEALTHINEERS AG: KEY STRATERGIES
TABLE 123. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 124. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 125. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 126. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
TABLE 127. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 128. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 129. HOLOGIC, INC.: KEY EXECUTIVES
TABLE 130. HOLOGIC, INC.: COMPANY SNAPSHOT
TABLE 131. HOLOGIC, INC.: PRODUCT SEGMENTS
TABLE 132. HOLOGIC, INC.: SERVICE SEGMENTS
TABLE 133. HOLOGIC, INC.: PRODUCT PORTFOLIO
TABLE 134. HOLOGIC, INC.: KEY STRATERGIES
TABLE 135. BIOMERIEUX SA: KEY EXECUTIVES
TABLE 136. BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 137. BIOMERIEUX SA: PRODUCT SEGMENTS
TABLE 138. BIOMERIEUX SA: SERVICE SEGMENTS
TABLE 139. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 140. BIOMERIEUX SA: KEY STRATERGIES
TABLE 141. QIAGEN NV.: KEY EXECUTIVES
TABLE 142. QIAGEN NV.: COMPANY SNAPSHOT
TABLE 143. QIAGEN NV.: PRODUCT SEGMENTS
TABLE 144. QIAGEN NV.: SERVICE SEGMENTS
TABLE 145. QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 146. QIAGEN NV.: KEY STRATERGIES
TABLE 147. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 148. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 149. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 150. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
TABLE 151. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 152. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 153. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 154. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 155. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 156. DANAHER CORPORATION: SERVICE SEGMENTS
TABLE 157. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 158. DANAHER CORPORATION: KEY STRATERGIES
TABLE 159. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 160. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 161. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 162. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
TABLE 163. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 164. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 01. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 06. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
TABLE 07. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR NUCLEIC ACID SEQUENCING, BY REGION, 2022-2032 ($MILLION)
TABLE 08. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2022-2032 ($MILLION)
TABLE 09. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 11. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 12. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC DISORDER, BY REGION, 2022-2032 ($MILLION)
TABLE 13. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR CANCER SCREENING, BY REGION, 2022-2032 ($MILLION)
TABLE 14. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 22. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 25. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 26. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 28. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 31. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 32. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 35. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 36. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 38. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 41. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 44. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 45. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 47. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 57. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 60. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 63. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 74. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 75. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 76. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 79. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 80. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 81. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 82. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 83. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 84. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 85. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 86. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 88. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 90. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 91. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 92. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 93. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 94. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 95. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 96. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 97. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 98. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 99. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 100. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 101. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 102. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 103. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
TABLE 104. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 105. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 106. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 107. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 108. ABBOTT LABORATORIES: SERVICE SEGMENTS
TABLE 109. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 110. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 111. BECTON DICKINSON & COMPANY: KEY EXECUTIVES
TABLE 112. BECTON DICKINSON & COMPANY: COMPANY SNAPSHOT
TABLE 113. BECTON DICKINSON & COMPANY: PRODUCT SEGMENTS
TABLE 114. BECTON DICKINSON & COMPANY: SERVICE SEGMENTS
TABLE 115. BECTON DICKINSON & COMPANY: PRODUCT PORTFOLIO
TABLE 116. BECTON DICKINSON & COMPANY: KEY STRATERGIES
TABLE 117. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
TABLE 118. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 119. SIEMENS HEALTHINEERS AG: PRODUCT SEGMENTS
TABLE 120. SIEMENS HEALTHINEERS AG: SERVICE SEGMENTS
TABLE 121. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 122. SIEMENS HEALTHINEERS AG: KEY STRATERGIES
TABLE 123. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 124. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 125. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 126. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
TABLE 127. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 128. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 129. HOLOGIC, INC.: KEY EXECUTIVES
TABLE 130. HOLOGIC, INC.: COMPANY SNAPSHOT
TABLE 131. HOLOGIC, INC.: PRODUCT SEGMENTS
TABLE 132. HOLOGIC, INC.: SERVICE SEGMENTS
TABLE 133. HOLOGIC, INC.: PRODUCT PORTFOLIO
TABLE 134. HOLOGIC, INC.: KEY STRATERGIES
TABLE 135. BIOMERIEUX SA: KEY EXECUTIVES
TABLE 136. BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 137. BIOMERIEUX SA: PRODUCT SEGMENTS
TABLE 138. BIOMERIEUX SA: SERVICE SEGMENTS
TABLE 139. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 140. BIOMERIEUX SA: KEY STRATERGIES
TABLE 141. QIAGEN NV.: KEY EXECUTIVES
TABLE 142. QIAGEN NV.: COMPANY SNAPSHOT
TABLE 143. QIAGEN NV.: PRODUCT SEGMENTS
TABLE 144. QIAGEN NV.: SERVICE SEGMENTS
TABLE 145. QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 146. QIAGEN NV.: KEY STRATERGIES
TABLE 147. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 148. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 149. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 150. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
TABLE 151. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 152. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 153. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 154. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 155. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 156. DANAHER CORPORATION: SERVICE SEGMENTS
TABLE 157. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 158. DANAHER CORPORATION: KEY STRATERGIES
TABLE 159. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 160. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 161. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 162. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
TABLE 163. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 164. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR NUCLEIC ACID SEQUENCING, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC DISORDER, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR CANCER SCREENING, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 26. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 27. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 35. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 36. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 37. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 38. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 41. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 42. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 43. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 45. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 46. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 47. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 48. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2022-2025)
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2025)
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2022-2025)
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET
FIGURE 55. TOP PLAYER POSITIONING, 2022
FIGURE 01. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR NUCLEIC ACID SEQUENCING, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC DISORDER, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR CANCER SCREENING, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 26. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 27. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 35. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 36. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 37. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 38. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 39. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 41. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 42. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 43. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 45. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 46. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 47. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 48. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2022-2025)
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2025)
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2022-2025)
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET
FIGURE 55. TOP PLAYER POSITIONING, 2022
